Serum L C3-II levels in type 2 diabetic patients with impaired renal functions

A total of 176 Turkish subjects were enrolled, of whom 26 were healthy, and 150 had type 2 diabetes mellitus. Under the light of American Diabetes Association criteria, we selected 150 patients and introduced them as type 2 DM. Patients were classified according to albumin urea ratio: 88 patients had macroalbuminuria (ACR > 300 mg/g), 20 patients had microalbuminuria (ACR between 30 and 300 mg/g), and 42 had normoalbuminuria (ACR < 30 mg/g). According to eGFR values, T2DM patients were divided into six categories [standard to high (G1), slightly decreased (G2), slightly to moderately decreased (G3a), moderate to severely decreased (G3b), severely decreased (G4), and renal failure (G5)]. Proteinuria severity and eGFR stages were evaluated together and divided into three groups (Stage 1: Normoalbuminuria+G1/G2, Stage 2: Microalbuminuria+G3a/G3b, Stage 3: Macroalbuminuria+G5/G4). There is no relationship between LC3-II levels and ACR in T2DM patients. LC3-II has sufficient performance in the differential diagnosis of severe proteinuria. [Display omitted] •LC3-II levels were high in type 2 DM patients with DKD.•LC3-II elevation is higher in patients with severe proteinuria and advanced stage DKD.•The increase in LC3-II is accompanied by an increase in BCL-2 and TGF-β1.•The reason for the decrease in IL-1β in DKD may be inhibition due to the increase in LC3-II.•The increase in LC3-II can prevent tubular apoptosis by inhibiting the decrease in BCL-2.•Podocin levels are related to LC3-II in DKD patients. This study was designed to evaluate serum LC3-II, BCL-2, IL-1β, TGF-β1, and podocin levels in. type 2 diabetes (T2DM) patients with renal dysfunction. 176 Turkish subjects were enrolled, of whom 26 were healthy, and 150 had T2DM. Patients. were classified according to albumin urea ratio: 88 patients had macroalbuminuria, 20. patients had microalbuminuria, and 42 had normoalbuminuria. T2DM patients were also. classified into three groups according to proteinuria and eGFR stages. Increased serum LC3-II levels in patients with T2DM with increased urinary albumin. extraction and impaired renal functions. There was a strong relationship between serum. LC3-II levels and serum BCL-2, IL-1β, TGF-β1, and Podocin levels. The efficiency of LC3- II as a diagnostic biomarker in the differential diagnosis of DM patients with. macroproteinuria from DM patients with normoproteinuria was 75.4%. It was thought that increased serum LC3-II levels in T2DM patients with impaired renal